Susquehanna International Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $258K | Buy |
185,700
+1,200
| +0.7% | +$1.65K | ﹤0.01% | 11198 |
|
|
2025
Q4 | $297K | Buy |
184,500
+134,300
| +268% | +$281K | ﹤0.01% | 9969 |
|
|
2025
Q3 | $137K | Sell |
50,200
-27,700
| -36% | -$92.1K | ﹤0.01% | 11352 |
|
|
2025
Q2 | $284K | Sell |
77,900
-77,700
| -50% | -$213K | ﹤0.01% | 10474 |
|
|
2025
Q1 | $299K | Buy |
155,600
+61,100
| +65% | +$125K | ﹤0.01% | 10077 |
|
|
2024
Q4 | $180K | Sell |
94,500
-13,700
| -13% | -$23.8K | ﹤0.01% | 10841 |
|
|
2024
Q3 | $143K | Sell |
108,200
-50,100
| -32% | -$66.9K | ﹤0.01% | 10788 |
|
|
2024
Q2 | $161K | Sell |
158,300
-39,400
| -20% | -$48.7K | ﹤0.01% | 10611 |
|
|
2024
Q1 | $362K | Sell |
197,700
-14,300
| -7% | -$22.9K | ﹤0.01% | 9268 |
|
|
2023
Q4 | $263K | Buy |
212,000
+76,400
| +56% | +$77.9K | ﹤0.01% | 10104 |
|
|
2023
Q3 | $155K | Buy |
135,600
+75,300
| +125% | +$96.7K | ﹤0.01% | 10520 |
|
|
2023
Q2 | $55.5K | Buy |
60,300
+3,700
| +7% | +$3.57K | ﹤0.01% | 11296 |
|
|
2023
Q1 | $31.7K | Buy |
56,600
+35,100
| +163% | +$26.8K | ﹤0.01% | 11890 |
|
|
2022
Q4 | $12.5K | Sell |
21,500
-41,000
| -66% | -$12.8K | ﹤0.01% | 11896 |
|
|
2022
Q3 | $20K | Sell |
62,500
-36,000
| -37% | -$14.1K | ﹤0.01% | 12599 |
|
|
2022
Q2 | $34K | Sell |
98,500
-252,400
| -72% | -$106K | ﹤0.01% | 12157 |
|
|
2022
Q1 | $253K | Buy |
350,900
+200,200
| +133% | +$428K | ﹤0.01% | 10691 |
|
|
2021
Q4 | $341K | Sell |
150,700
-184,600
| -55% | -$503K | ﹤0.01% | 10172 |
|
|
2021
Q3 | $966K | Sell |
335,300
-130,000
| -28% | -$371K | ﹤0.01% | 7651 |
|
|
2021
Q2 | $1.76M | Sell |
465,300
-67,400
| -13% | -$227K | ﹤0.01% | 6207 |
|
|
2021
Q1 | $1.8M | Sell |
532,700
-62,900
| -11% | -$227K | ﹤0.01% | 6172 |
|
|
2020
Q4 | $1.67M | Buy |
595,600
+42,500
| +8% | +$124K | ﹤0.01% | 5495 |
|
|
2020
Q3 | $1.39M | Buy |
553,100
+395,600
| +251% | +$3.47M | ﹤0.01% | 5339 |
|
|
2020
Q2 | $2.14M | Buy |
157,500
+72,800
| +86% | +$753K | ﹤0.01% | 4371 |
|
|
2020
Q1 | $642K | Sell |
84,700
-32,300
| -28% | -$251K | ﹤0.01% | 6396 |
|
|
2019
Q4 | $739K | Buy |
117,000
+62,600
| +115% | +$298K | ﹤0.01% | 6140 |
|
|
2019
Q3 | $213K | Sell |
54,400
-9,400
| -15% | -$40.3K | ﹤0.01% | 8977 |
|
|
2019
Q2 | $309K | Sell |
63,800
-65,100
| -51% | -$370K | ﹤0.01% | 8242 |
|
|
2019
Q1 | $1.06M | Buy |
128,900
+25,100
| +24% | +$172K | ﹤0.01% | 4933 |
|
|
2018
Q4 | $574K | Buy |
103,800
+48,700
| +88% | +$381K | ﹤0.01% | 5764 |
|
|
2018
Q3 | $487K | Buy |
55,100
+34,200
| +164% | +$306K | ﹤0.01% | 6584 |
|
|
2018
Q2 | $209K | Buy |
20,900
+10,600
| +103% | +$106K | ﹤0.01% | 8527 |
|
|
2018
Q1 | $98K | Buy |
+10,300
| New | +$144K | ﹤0.01% | 8710 |
|
|
2017
Q3 | – | Sell |
-20,000
| Closed | -$287K | – | 8745 |
|
|
2017
Q2 | $287K | Buy |
20,000
+6,000
| +43% | +$76.1K | ﹤0.01% | 7666 |
|
|
2017
Q1 | $129K | Sell |
14,000
-37,300
| -73% | -$364K | ﹤0.01% | 8275 |
|
|
2016
Q4 | $534K | Sell |
51,300
-163,800
| -76% | -$1.41M | ﹤0.01% | 6836 |
|
|
2016
Q3 | $1.95M | Sell |
215,100
-17,100
| -7% | -$145K | ﹤0.01% | 3612 |
|
|
2016
Q2 | $1.74M | Buy |
232,200
+144,900
| +166% | +$1.26M | ﹤0.01% | 3829 |
|
|
2016
Q1 | $787K | Buy |
87,300
+68,600
| +367% | +$556K | ﹤0.01% | 5560 |
|
|
2015
Q4 | $242K | Sell |
18,700
-73,400
| -80% | -$749K | ﹤0.01% | 8098 |
|
|
2015
Q3 | $890K | Buy |
92,100
+21,800
| +31% | +$200K | ﹤0.01% | 6002 |
|
|
2015
Q2 | $723K | Buy |
70,300
+35,600
| +103% | +$304K | ﹤0.01% | 6875 |
|
|
2015
Q1 | $386K | Buy |
+34,700
| New | +$369K | ﹤0.01% | 7564 |
|
Other funds holding AKBA
VCM
VPM
Susquehanna International Group's AKBA Position: Q1 2026 in Review
Susquehanna International Group increased its Akebia Therapeutics (AKBA) stake by 11% in Q1 2026, buying an estimated $102K and bringing the position to 722,119 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #7874.
Susquehanna International Group first reported a position in AKBA in Q2 2014 and has held it in 40 quarters since. The position peaked at $4.01M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Susquehanna International Group held 722,119 shares of Akebia Therapeutics worth $1M as of Q1 2026.
- Susquehanna International Group bought 74,406 Akebia Therapeutics shares in Q1 2026, an estimated $102K.
- Akebia Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7874 holding.
- Susquehanna International Group first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 40 quarters since.
- Susquehanna International Group's Akebia Therapeutics position peaked at $4.01M in Q1 2021.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.